Attached files
file | filename |
---|---|
8-K - FORM 8-K - Option Care Health, Inc. | y87223e8vk.htm |
EX-99.2 - EX-99.2 - Option Care Health, Inc. | y87223exv99w2.htm |
EX-10.1 - EX-10.1 - Option Care Health, Inc. | y87223exv10w1.htm |
Exhibit 99.1
BIOSCRIP REPORTS 2010 THIRD QUARTER RESULTS
Elmsford, NY November 2, 2010 BioScrip, Inc. (Nasdaq: BIOS) today announced 2010 third quarter
revenue of $441.2 million and net income of $2.0 million or $0.04 earnings per diluted share (EPS).
Adjusted EBITDA for the quarter was $18.1 million.
Third Quarter Results
| Revenue was $441.2 million; | ||
| Adjusted EBITDA of $18.1 million compared to $8.9 million in 2009; | ||
| Net income of $2.0 million or $0.04 EPS compared to prior year of $5.7 million or $0.14 EPS; | ||
| Average cash balances increased $14.4 million over the second quarter, with an average balance of $64.1 million; and | ||
| Reduced debt $2.9 million and in compliance with all debt covenants. |
Although the fundamentals of BioScrip are strong and we remain excited about the Companys ongoing
prospects, we recognize that we did not meet our guidance, said Rick Smith, President and Chief
Operating Officer of BioScrip. In our Infusion/Home Health segment, we were successful in posting
solid organic growth, but revenue was slightly below our expectations. On the incremental $5.2
million of revenue in this segment, an additional $1.0 million, or 20%, of Adjusted EBITDA was
generated from the second quarter to the third, reflecting the strength of the higher margin home
infusion therapies and the cost synergies we are realizing from the CHS acquisition. In our
Pharmacy Services segment, revenue exceeded our expectations but the mix was not as strong as we
anticipated. While new patient census grew, it was offset by lower-than-anticipated patient refill
patterns.
Mr. Smith added, Overall our gross profit margins were impacted by IVIG product allocations and a
manufacturer recall requiring us to fill prescriptions with a higher cost product, elimination of
an industry-wide brand product rebate, conversion of certain CHS patients into a long-term
contractual relationship and changes in reimbursement from certain payors.
We are examining all aspects of our business model and we intend to improve the quality of our
revenue stream and reduce our overhead structure. As a result of the Company not meeting its
expectations, we have accelerated a strategic assessment of our business lines and our operating
cost structure, Mr. Smith concluded.
Succession Announcement
As announced earlier today, the Company appointed Rick Smith, currently President and Chief
Operating Officer, as Chief Executive Officer. Rich Friedman, currently Chairman and Chief
Executive Officer, will serve as Non-Executive Chairman of the Board of Directors. Both changes are
effective January 1, 2011.
2010 Guidance
Based on its year-to-date results, BioScrip is withdrawing its revenue, gross profit, net income,
Adjusted EBITDA and EPS financial guidance for the full-year 2010, as well as fourth quarter 2010
revenue
guidance. Management intends to assess its business, operations and 2011 outlook and expects to
communicate its plans in January 2011.
Results of Operations
Third Quarter 2010 versus Third Quarter 2009
Revenue for the third quarter of 2010 totaled $441.2 million compared to $333.5 million for the
same period a year ago, an increase of 32.3%. Pharmacy Services revenue for the third quarter of
2010 was $329.3 million compared to $296.7 million for the prior year period, an increase of $32.6
million or 11.0%. New revenue from the recently completed acquisition of the pharmacy operations of
drugstore.com was $3.6 million. Infusion/Home Health Services revenue for the third quarter of 2010
was $111.8 million compared to $36.8 million in the third quarter of 2009, an increase of $75.0
million. CHS revenues contributed $68.0 million during the third quarter of 2010. Excluding the CHS
revenues, Infusion/Home Health Services revenues increased 19.1%.
Consolidated gross profit for the third quarter of 2010 was $75.4 million, or 17.1% of revenue,
compared to $41.5 million, or 12.4% of revenue for the third quarter of 2009. The increase in gross
profit and gross margin percentage from 2009 to 2010 is the result of the contribution from CHS
during the quarter and purchasing synergies, partially offset by previously disclosed pricing
concessions, delays in brand to generic conversions, product allocations and last years AWP
settlement. Sequentially, consolidated gross profit margins declined 0.7% to 17.1% primarily as a
result of IVIG product allocations and a manufacturer recall which required us to fill
prescriptions with a higher cost product, elimination of an industry-wide brand product rebate,
conversion of certain CHS patients into a long-term contractual relationship and changes in
reimbursement from certain payors versus the second quarter.
Third quarter 2010 operating profit was $12.2 million, or 2.8% of revenue, compared to an operating
profit of $6.7 million, or 2.0% of revenue, for the third quarter of 2009. Operating profit in the
third quarter of 2010 includes $1.3 million of amortization expense and $1.0 million of
transaction, integration and severance related expenses associated with the CHS and drugstore.com
acquisitions.
During the third quarter of 2010, BioScrip generated $25.7 million of segment Adjusted EBITDA, or
5.8% of total revenue. Consolidated Adjusted EBITDA includes corporate expenses, which are not
allocated to the segments. This compares to $15.8 million, or 4.7% of total revenue in the prior
year period. The Pharmacy Services segment generated $10.7 million of segment Adjusted EBITDA, or
3.3% of Pharmacy Services revenue. This compares to $13.2 million, or 4.5% of that segments
revenue in the prior period. The Infusion/Home Health segment generated $14.9 million of Adjusted
EBITDA, or 13.4% of revenue. This compares to $2.6 million, or 7.0% of Infusion/Home Health
Services revenue in the third quarter of 2009.
On a consolidated basis, BioScrip reported $18.1 million of Adjusted EBITDA during the third
quarter of 2010, or 4.1% of total revenue compared to $8.9 million, or 2.7% of total revenue in the
prior year period.
Interest expense in the third quarter of 2010 was $8.1 million compared to $0.4 million in the
third quarter of 2009.
The Company recorded a provision for income taxes of $2.1 million for the third quarter of 2010 on
pre-tax income of $4.1 million, a 51.9% effective tax rate. The increased rate results from an
additional $0.3 million charge relating to a reduction in the estimated value of our state deferred
tax assets. This compares to $0.5 million of income tax expense on pre-tax income of $6.2 million,
a 7.5% effective tax
rate for the prior year period. The 2009 tax rate was lower due to utilizing the valuation
allowance against our deferred tax assets, which was reversed in the fourth quarter of 2009.
Net income for the third quarter was $2.0 million, or $0.04 per diluted share, compared to $5.7
million, or $0.14 per diluted share, in the prior year period.
Nine Months Ended 2010 versus Nine Months Ended 2009
Revenue for the nine months ended September 30, 2010 was $1.2 billion compared to $988.0 million
for the comparable period a year ago. Pharmacy Services segment revenue for the nine months ended
September 30, 2010 was $923.6 million as compared to revenue of $880.4 million for the same period
a year ago, an increase of $43.2 million, or 4.9%. The increase for the year was primarily related
to new contracts, the expansion of patients served and industry wide drug inflation partially
offset by pricing concessions and last years AWP settlement. Infusion/Home Health Services segment
revenue for the nine months ended September 30, 2010 was $264.6 million, as compared to $107.6
million for the same period a year ago, an increase of $157.0 million. CHS revenues contributed
$137.8 million for the nine months ended September 30, 2010. Excluding the CHS revenues,
Infusion/Home Health Services segment revenue increased 17.9% over the prior year period.
Consolidated gross profit for the nine months ended September 30, 2010 was $187.8 million compared
to $115.9 million for the same period a year ago. Consolidated gross profit as a percent of revenue
for the nine months ended September 30, 2010 was 15.8%, compared to 11.7% for the same period of
2009.
Consolidated operating profit for the nine months ended September 30, 2010 was $19.4 million, or
1.6% of total revenue, compared to $16.1 million, or 1.6% of revenue, for the same period a year
ago.
Operating profit for the nine months ended September 30, 2010 includes $2.2 million of amortization
expense and $7.1 million of transaction, integration and severance related expenses associated with
the CHS and drugstore.com acquisitions.
For the nine months ended September 30, 2010, BioScrip generated $62.8 million of segment Adjusted
EBITDA, or 5.3% of total revenue. This compares to $41.9 million, or 4.2% of total revenue for the
prior year period. Pharmacy Services segment generated $31.1 million of segment Adjusted EBITDA, or
3.4% of Pharmacy Services segment revenue. This compares to $34.5 million, or 3.9% of that
segments revenue in the prior period. Infusion/Home Health segment reported $31.7 million of
segment Adjusted EBITDA, or 12.0% of Infusion/Home Health segment revenue. This compares to $7.4
million, or 6.9% of Infusion/Home Health Services segment revenue, in the prior year period.
On a consolidated basis, BioScrip reported $39.2 million of Adjusted EBITDA for the nine month
period ended September 30, 2010, or 3.3% of total revenue compared to $22.1 million, or 2.2% of
total revenues in the prior year period.
Interest expense for the nine months ended September 30, 2010 was $19.5 million, which includes
$2.3 million associated with the Companys bridge loan. Interest expense for the comparable period
in 2009 was $1.5 million.
Income tax expense was $2.0 million for the nine months ended September 30, 2010 on a pre-tax net
loss of $0.1 million. The income tax expense for the year is the result of the non deductible
transaction expenses associated with the CHS acquisition and the revaluation of certain state
deferred tax assets. This compares to a $1.2 million income tax expense on pre-tax income of $14.7
million same period a year ago.
Net loss for the nine months ended September 30, 2010 was $2.1 million, or $0.04 per share. This
compares to net income of $13.4 million or $0.34 per diluted share for the same period last year.
Liquidity
On September 30, 2010, the Company had $51.0 million of cash with an average cash balance of $64.1
million during the quarter. In addition, the $50.0 million revolving credit facility remains
undrawn. Free cash flow (Adjusted EBITDA less debt service, cash interest, cash taxes and cash
capital expenditure) during the third quarter was $12.1 million.
Conference Call
BioScrip will host a conference call to discuss its third quarter 2010 financial results on
November 2, 2010 at 8:30 a.m. Eastern Time. Interested parties may participate in the conference
call by dialing 800-909-4195 (US), or 212-231-2905 (International), 5-10 minutes prior to the start
of the call. A replay of the conference call will be available shortly after the calls conclusion
on Tuesday, November 2, through 10:30 a.m. Eastern Time on Wednesday, November 17, by dialing
800-633-8284 (US), or 402-977-9140 (International), and entering reservation number #21485382. An
audio web cast and archive of the conference call will also be available under the investor
relations section of the BioScrip website at www.bioscrip.com.
About BioScrip, Inc.
BioScrip, Inc. (www.bioscrip.com) (Nasdaq: BIOS) is a national provider of specialty pharmacy and
home care products and services that partners with patients, physicians, hospitals, healthcare
payors and pharmaceutical manufacturers to provide clinical management solutions and delivery of
cost-effective access to prescription medications. Our services are designed to improve clinical
outcomes for chronic and acute healthcare conditions while controlling overall healthcare costs.
Forward Looking Statements Safe Harbor
This press release may contain statements which constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the
intent, belief or current expectations of the Company, its directors, or its officers with respect
to the future operating performance of the Company, Investors are cautioned that any such
forward-looking statements are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from those in the forward-looking
statements as a result of various factors. Important factors that could cause such differences are
described in the Companys periodic filings with the Securities and Exchange Commission.
EBITDA or earnings before interest, taxes, depreciation and amortization (EBITDA) and Adjusted
EBITDA, which includes equity-based compensation and transaction, integration and severance and bad
debt relating to CAP contract termination, are non-GAAP financial measures as defined under U.S.
Securities and Exchange Commission Regulation G. As required by Regulation G, BioScrip has provided
on Schedule 4 a reconciliation of this measure to the most comparable GAAP financial measure. The
non-GAAP measure presented provides important insight into the ongoing operations and a meaningful
benchmark to evidence the Companys continuing profitability trend.
Contacts:
BioScrip, Inc.
Stanley G. Rosenbaum, Executive Vice President and Chief Financial Officer
952-979-3768
or
Ed Trissel
Joele Frank, Wilkinson Brimmer Katcher
212-335-4449
Stanley G. Rosenbaum, Executive Vice President and Chief Financial Officer
952-979-3768
or
Ed Trissel
Joele Frank, Wilkinson Brimmer Katcher
212-335-4449
Schedule 1
BIOSCRIP, INC
CONSOLIDATED BALANCE SHEETS
(in thousands, except for share amounts)
CONSOLIDATED BALANCE SHEETS
(in thousands, except for share amounts)
September 30, | December 31, | |||||||
2010 | 2009 | |||||||
(unaudited) | ||||||||
ASSETS |
||||||||
Current assets |
||||||||
Cash and cash equivalents |
$ | 50,979 | $ | | ||||
Receivables, less allowance for doubtful accounts of $16,408 and $11,504
at September 30, 2010 and December 31, 2009, respectively |
186,474 | 151,113 | ||||||
Inventory |
66,322 | 51,256 | ||||||
Deferred taxes |
19,960 | 12,913 | ||||||
Prepaid expenses and other current assets |
16,519 | 3,999 | ||||||
Total current assets |
340,254 | 219,281 | ||||||
Property and equipment, net |
22,723 | 15,454 | ||||||
Deferred taxes |
17,414 | 26,793 | ||||||
Goodwill |
323,798 | 24,498 | ||||||
Intangible assets, net |
32,101 | | ||||||
Deferred financing costs |
5,440 | | ||||||
Other non-current assets |
2,151 | 1,194 | ||||||
Total assets |
$ | 743,881 | $ | 287,220 | ||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
Current liabilities |
||||||||
Current portion of long-term debt |
$ | 3,864 | $ | 30,389 | ||||
Accounts payable |
84,782 | 74,535 | ||||||
Claims payable |
4,598 | 4,068 | ||||||
Amounts due to plan sponsors |
16,170 | 4,938 | ||||||
Deferred revenue |
3,527 | | ||||||
Accrued expenses and other current liabilities |
46,577 | 14,273 | ||||||
Total current liabilities |
159,518 | 128,203 | ||||||
Long-term debt, net of current portion |
314,752 | | ||||||
Other non-current liabilities |
3,796 | 3,224 | ||||||
Total liabilities |
478,066 | 131,427 | ||||||
Stockholders equity |
||||||||
Preferred stock, $.0001 par value; 5,000,000 shares authorized;
no shares issued or outstanding |
$ | | $ | | ||||
Common stock, $.0001 par value; 125,000,000 shares authorized; shares issued: 56,632,871 and 42,766,478, respectively; shares outstanding;
53,688,338 and
39,675,865, respectively |
6 | 4 | ||||||
Treasury stock, shares at cost: 2,658,963 and 2,647,613, respectively |
(10,496 | ) | (10,367 | ) | ||||
Additional paid-in capital |
366,901 | 254,677 | ||||||
Accumulated deficit |
(90,596 | ) | (88,521 | ) | ||||
Total stockholders equity |
265,815 | 155,793 | ||||||
Total liabilities and stockholders equity |
$ | 743,881 | $ | 287,220 | ||||
Schedule 2
BIOSCRIP, INC
CONSOLIDATED STATEMENTS OF OPERATIONS (1)
(unaudited and in thousands, except per share amounts)
CONSOLIDATED STATEMENTS OF OPERATIONS (1)
(unaudited and in thousands, except per share amounts)
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
Revenue |
$ | 441,153 | $ | 333,476 | $ | 1,188,251 | $ | 987,974 | ||||||||
Cost of revenue |
365,769 | 291,980 | 1,000,426 | 872,100 | ||||||||||||
Gross profit |
75,384 | 41,496 | 187,825 | 115,874 | ||||||||||||
% of Revenue |
17.1 | % | 12.4 | % | 15.8 | % | 11.7 | % | ||||||||
Operating expenses |
||||||||||||||||
Selling, general and administrative expenses |
55,950 | 32,402 | 146,978 | 94,335 | ||||||||||||
Bad debt expense |
5,309 | 2,433 | 12,536 | 5,410 | ||||||||||||
Acquisition and integration expenses |
595 | | 6,694 | | ||||||||||||
Amortization of intangibles |
1,326 | | 2,196 | | ||||||||||||
Total operating expense |
63,180 | 34,835 | 168,404 | 99,745 | ||||||||||||
% of Revenue |
14.3 | % | 10.4 | % | 14.2 | % | 10.1 | % | ||||||||
Income from operations |
12,204 | 6,661 | 19,421 | 16,129 | ||||||||||||
Interest expense, net |
8,122 | 447 | 19,515 | 1,471 | ||||||||||||
Income (loss) before income taxes |
4,082 | 6,214 | (94 | ) | 14,658 | |||||||||||
Income tax expense |
2,117 | 467 | 1,981 | 1,249 | ||||||||||||
Net income (loss) |
$ | 1,965 | $ | 5,747 | $ | (2,075 | ) | $ | 13,409 | |||||||
Basic weighted average shares |
53,425 | 38,961 | 49,232 | 38,807 | ||||||||||||
Diluted weighted average shares |
54,210 | 40,184 | 49,232 | 39,345 | ||||||||||||
Basic net income (loss) per share |
$ | 0.04 | $ | 0.15 | $ | (0.04 | ) | $ | 0.35 | |||||||
Diluted net income (loss) per share |
$ | 0.04 | $ | 0.14 | $ | (0.04 | ) | $ | 0.34 |
Schedule 3
BIOSCRIP, INC
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited and in thousands)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited and in thousands)
Nine Months Ended | ||||||||
September 30, | ||||||||
2010 | 2009 | |||||||
Cash flows from operating activities: |
||||||||
Net (loss) income |
$ | (2,075 | ) | $ | 13,409 | |||
Adjustments to reconcile net (loss) income to net cash
provided by operating activities: |
||||||||
Depreciation |
6,211 | 3,596 | ||||||
Amortization of intangible assets |
2,196 | | ||||||
Amortization of deferred financing costs |
1,272 | | ||||||
Change in deferred income tax |
1,197 | 562 | ||||||
Compensation under stock-based compensation plans |
2,726 | 2,385 | ||||||
Loss on disposal of fixed assets |
125 | | ||||||
Bad debt expense |
12,536 | 5,410 | ||||||
Changes in assets and liabilities, net of acquired business: |
||||||||
Receivables, net of bad debt expense |
(10,564 | ) | 5,913 | |||||
Inventory |
(10,834 | ) | (2,606 | ) | ||||
Prepaid expenses and other assets |
(6,618 | ) | (1,014 | ) | ||||
Accounts payable |
7,100 | (14,027 | ) | |||||
Claims payable |
530 | (1,002 | ) | |||||
Amounts due to plan sponsors |
3,051 | 305 | ||||||
Accrued expenses and other liabilities |
(963 | ) | 1,048 | |||||
Net cash provided by operating activities |
5,890 | 13,979 | ||||||
Cash flows from investing activities: |
||||||||
Purchases of property and equipment, net |
(6,747 | ) | (4,522 | ) | ||||
Cash consideration paid for Option Health earn-out |
(1,000 | ) | | |||||
Cash consideration paid to CHS, net of cash acquired |
(92,464 | ) | | |||||
Cash consideration paid to DS Pharmacy |
(4,969 | ) | | |||||
Net cash used in investing activities |
(105,180 | ) | (4,522 | ) | ||||
Cash flows from financing activities: |
||||||||
Proceeds from new credit facility, net of fees paid to issuers |
319,000 | | ||||||
Borrowings on line of credit |
300,310 | 997,920 | ||||||
Repayments on line of credit |
(330,699 | ) | (1,008,747 | ) | ||||
Repayments of capital leases |
(72 | ) | | |||||
Principal payments on CHS long-term debt, paid at closing |
(128,952 | ) | | |||||
Principal payments on long-term debt |
(1,250 | ) | | |||||
Repayment of note payable |
(2,250 | ) | | |||||
Deferred financing costs |
(8,680 | ) | | |||||
Net proceeds from exercise of employee stock compensation plans |
2,990 | 1,448 | ||||||
Surrender of stock to satisfy minimum tax withholding |
(128 | ) | (78 | ) | ||||
Net cash provided by (used in) financing activities |
150,269 | (9,457 | ) | |||||
Net change in cash and cash equivalents |
50,979 | | ||||||
Cash and cash equivalents beginning of period |
| | ||||||
Cash and cash equivalents end of period |
$ | 50,979 | $ | | ||||
DISCLOSURE OF CASH FLOW INFORMATION: |
||||||||
Cash paid during the period for interest |
$ | 5,038 | $ | 1,432 | ||||
Cash paid during the period for income taxes |
$ | 1,803 | $ | 741 | ||||
Schedule 4
BIOSCRIP, INC
Reconciliation between GAAP and Non-GAAP Measures
(unaudited and in thousands)
Reconciliation between GAAP and Non-GAAP Measures
(unaudited and in thousands)
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
Results of Operations: |
||||||||||||||||
Revenue: |
||||||||||||||||
Infusion and Home Health Services |
$ | 111,849 | $ | 36,809 | $ | 264,625 | $ | 107,613 | ||||||||
Pharmacy Services |
329,304 | 296,667 | 923,626 | 880,361 | ||||||||||||
Total |
$ | 441,153 | $ | 333,476 | $ | 1,188,251 | $ | 987,974 | ||||||||
Adjusted EBITDA by Segment before corporate overhead: |
||||||||||||||||
Infusion and Home Health Services |
$ | 14,942 | $ | 2,586 | $ | 31,702 | $ | 7,420 | ||||||||
Pharmacy Services |
10,731 | 13,224 | 31,120 | 34,521 | ||||||||||||
Total Segment Adjusted EBITDA |
25,673 | 15,810 | 62,822 | 41,941 | ||||||||||||
Corporate overhead |
(7,602 | ) | (6,896 | ) | (23,646 | ) | (19,831 | ) | ||||||||
Consolidated Adjusted EBITDA |
$ | 18,071 | $ | 8,914 | $ | 39,176 | $ | 22,110 | ||||||||
Interest expense, net |
(8,122 | ) | (447 | ) | (19,515 | ) | (1,471 | ) | ||||||||
Income tax expense |
(2,117 | ) | (467 | ) | (1,981 | ) | (1,249 | ) | ||||||||
Depreciation |
(2,404 | ) | (1,356 | ) | (6,211 | ) | (3,596 | ) | ||||||||
Amortization |
(1,326 | ) | | (2,196 | ) | | ||||||||||
Stock-based compensation expense |
(1,097 | ) | (897 | ) | (2,726 | ) | (2,385 | ) | ||||||||
Acquisition, integration and severance expenses |
(1,040 | ) | | (7,139 | ) | | ||||||||||
Bad debt expense related to contract termination |
| | (1,483 | ) | | |||||||||||
Net income (loss) |
$ | 1,965 | $ | 5,747 | $ | (2,075 | ) | $ | 13,409 | |||||||
Supplemental Operating Data |
||||||||||||||||
Capital Expenditures: |
||||||||||||||||
Infusion and Home Health Services |
$ | 977 | $ | 48 | $ | 2,229 | $ | 376 | ||||||||
Pharmacy Services |
1,104 | 545 | 3,044 | 3,010 | ||||||||||||
Corporate unallocated |
324 | | 1,474 | 1,136 | ||||||||||||
Total |
$ | 2,405 | $ | 593 | $ | 6,747 | $ | 4,522 | ||||||||
Depreciation Expense: |
||||||||||||||||
Infusion and Home Health Services |
$ | 1,128 | $ | 277 | $ | 2,381 | $ | 904 | ||||||||
Pharmacy Services |
954 | 858 | 3,019 | 1,950 | ||||||||||||
Corporate unallocated |
322 | 221 | 811 | 742 | ||||||||||||
Total |
$ | 2,404 | $ | 1,356 | $ | 6,211 | $ | 3,596 | ||||||||
Total Assets |
||||||||||||||||
Infusion and Home Health Services |
$ | 438,705 | $ | 52,954 | ||||||||||||
Pharmacy Services |
143,153 | 121,081 | ||||||||||||||
Corporate unallocated |
162,023 | 66,145 | ||||||||||||||
Total |
$ | 743,881 | $ | 240,180 | ||||||||||||
Goodwill |
||||||||||||||||
Infusion and Home Health Services |
$ | 299,300 | $ | | ||||||||||||
Pharmacy Services |
24,498 | 24,498 | ||||||||||||||
Total |
$ | 323,798 | $ | 24,498 | ||||||||||||